GENINUS Inc., a bioinformation analysis company, engages in the research and development, manufacture, and sale of next generation sequencing (NGS) - based genome analysis solutions in South Korea. It offers CancerSCAN, an NGS-based cancer genome diagnosis solution; LiquidSCAN, a liquid biopsy NGS test; and Celinus, a single-cell analysis solution for ultra-precise genome analysis. The company also provides HealthSCAN, a genetic test service; WithMe, a service that analyzes gut bacteria characteristics related to the risk of chronic diseases; and OncoSTATION, an automated clinical genome information analysis solution. It serves hospitals, pharmaceutical companies, and researchers. The company was incorporated in 2018 and is based in Seoul, South Korea.
Stock data | 2024 | Change |
---|---|---|
Price | $1.13 | N/A |
Market Cap | $37.41M | N/A |
Shares Outstanding | 33.13M | N/A |
Employees | 0 | N/A |